title: Addressing the challenges of cardiorenal syndrome.
abstract: In heart failure, as the heart gets worse, often so do the kidneys, complicating the treatment of heart failure and worsening the prognosis. This article addresses challenges in the use of diuretics, angiotensin-converting enzyme (ACE) inhibitors, and other therapies in the cardiorenal syndrome, as well as novel therapies that hold promise, such as arginine vasopressin antagonists, adenosine A1 receptor antagonists, and ultrafiltration.
authors.affiliation: Cardiology Division, Vanderbilt University, Nashville, TN 37232-6300, USA.
authors.forename: Carrie
authors.initials: C
authors.lastname: Geisberg
authors.forename: Javed
authors.initials: J
authors.lastname: Butler
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D005919:Glomerular Filtration Rate; D006333:Heart Failure / Q000150:complications* / Q000503:physiopathology; D006801:Humans; D011379:Prognosis; D051437:Renal Insufficiency / Q000209:etiology* / Q000503:physiopathology; D013577:Syndrome
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D004232:Diuretics